gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Company profile
Ticker
GMDAQ
Exchange
Website
CEO
Julian Adams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GMDAQ stock data
Latest filings (excl ownership)
8-K
Bankruptcy or Receivership
22 Apr 24
8-K/A
Other Events
11 Apr 24
8-K/A
Other Events
5 Apr 24
8-K/A
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
27 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Gamida Cell Actively Pursuing Strategic Alternatives
29 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Departure of Directors or Certain Officers
18 Dec 23
Transcripts
GMDAQ
Earnings call transcript
2023 Q4
27 Mar 24
GMDAQ
Earnings call transcript
2023 Q3
14 Nov 23
GMDAQ
Earnings call transcript
2023 Q2
14 Aug 23
GMDAQ
Earnings call transcript
2023 Q1
15 May 23
GMDAQ
Earnings call transcript
2023 Q4
27 Mar 23
GMDAQ
Earnings call transcript
2022 Q3
14 Nov 22
GMDAQ
Earnings call transcript
2022 Q2
15 Aug 22
GMDAQ
Earnings call transcript
2022 Q1
10 May 22
GMDAQ
Earnings call transcript
2021 Q4
15 Mar 22
GMDAQ
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
SC 13G/A
LEVIN CAPITAL STRATEGIES, L.P.
1 Apr 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
LEVIN CAPITAL STRATEGIES, L.P.
8 Feb 24
4
KENNETH I MOCH
2 Feb 24
4
STEPHEN T WILLS
2 Feb 24
4
Shawn Tomasello
2 Feb 24
4
JULIAN ADAMS
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.43 mm | 60.43 mm | 60.43 mm | 60.43 mm | 60.43 mm | 60.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.01 mm | 6.42 mm | 6.19 mm | 6.59 mm |
Cash used (since last report) | n/a | n/a | 40.97 mm | 43.72 mm | 42.18 mm | 44.88 mm |
Cash remaining | n/a | n/a | 19.46 mm | 16.71 mm | 18.25 mm | 15.55 mm |
Runway (months of cash) | n/a | n/a | 3.2 | 2.6 | 2.9 | 2.4 |
Institutional ownership, Q4 2022
32.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 14 |
Closed positions | 21 |
Increased positions | 11 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 27.46 bn |
Total shares | 50.17 mm |
Total puts | 34.80 k |
Total calls | 79.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
AI Gamida | 9.74 mm | $19.19 mm |
FMR | 6.92 mm | $8.93 bn |
Community US Fund Management | 5.04 mm | $8.17 mm |
Novartis Pharma | 4.34 mm | $5.59 mm |
Highbridge Capital Management | 4.22 mm | $0.00 |
Rock Springs Capital Management | 4.12 mm | $5.31 bn |
Meitav Dash Investments | 3.66 mm | $4.63 bn |
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet | 2.21 mm | $2.80 bn |
Israel HealthCare Ventures 2 | 1.89 mm | $15.86 mm |
EMITF Elbit Imaging | 1.83 mm | $15.34 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Ivan M. Borrello | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 232,300 |
31 Jan 24 | Tomasello Shawn | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 241,977 |
31 Jan 24 | Julian Adams | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 423,750 |
31 Jan 24 | Wills Stephen T | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 256,177 |
31 Jan 24 | Moch Kenneth I | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 232,300 |
News
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
3 Apr 24
Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
3 Apr 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
28 Mar 24
Gold Moves Higher; Velo3D Shares Plummet
27 Mar 24
Press releases
XORTX Welcomes New Member to the Board of Directors
8 Apr 24
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
27 Mar 24
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
22 Mar 24
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
23 Feb 24
Gamida Cell Actively Pursuing Strategic Alternatives
29 Jan 24